Pacific Biosciences of California Profit Margin

The latest profit margin for PACB is -82.49% as of June 2026. That compares with -336.4% in the prior-year period — up 75.5% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Pacific Biosciences of California's historical trend and sector peers before judging valuation or financial health.

Over the past year, PACB's profit margin moved from -336.4% to -82.49% — a 75.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pacific Biosciences of California's valuation or profitability profile.

Against Healthcare companies, PACB currently prints -82.49% for profit margin, while the sector average sits near 13.89%. That is roughly 693.8% below the sector mean. Large gaps often invite a closer look at Pacific Biosciences of California's growth, margins, and balance sheet.

Profit Margin shows how effectively Pacific Biosciences of California converts resources into returns. At -82.49%, PACB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -336.4% in the prior-year period — up 75.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PACB's profit margin (-82.49%), review year-over-year change from -336.4%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.